News Releases News Releases HOME HOME




January 17,2002

Pabron Ace Tablet to Be Launched
Combination Cold Remedy with Precision-Targeted
Effectiveness
Contains Triple Set of Special Ingredients


Pabron Ace Tablet image


Taisho Pharmaceutical Co., Ltd. (President: Akira Uehara) will launch sales of Pabron Ace Tablet, a combination cold remedy, on February 1. This new self-medication product shows outstanding effectiveness against the four symptoms that are most distressing when people have colds.

Pabron Ace Tablet targets four hard-to-bear cold symptoms-sore throat, cough, fever, and runny or stuffy nose-with a triple set of special ingredients: bromohexine hydrochloride, ibuprofen, and lysozyme chloride. In clinical trials, Pabron Ace Tablet proved remarkably effective, with a 98.6% overall improvement rate among cold sufferers.

Since Taisho Pharmaceutical's launch of Pabron cough medicine in 1927, the company has continually expanded the Pabron line, developing new products and reformulating them to meet consumers' needs for combination cold remedy. Pabron Ace Tablet is a result of that ongoing drive to relieve the suffering caused by the common cold. It targets the four symptoms that respondents in a questionnaire study of 1,000 persons who had taken cold remedies listed most often as "particularly distressing symptoms I would like to clear up immediately." Pabron Ace Tablet is thus a combination cold remedy that meets the growing consumer demand for such products, demand that has risen with the spread of self-medication.


Principal Product Features
1. A triple set of special ingredients that tackles all four cold symptoms
2. Small, easy-to-swallow coated tablets
3. A combination cold remedy formulated for adults only (age 15 and above), with precisely targeted effectiveness.

Product Specifications
Name Pabron Ace Tablet
Suggested Retail Price 30 tablet package, 1,580 yen
45 tablet package, 1,980 yen
Active ingredients (per 3-tablet dose)
Ibuprofen 150 mg
Bromohexine hydrochloride 4 mg
Dihydrocodeine Phosphate 8 mg
Noscapin 16 mg
dl-Methylephedrine hydrochloride 20 mg
Lysozyme chloride 30 mg (potency)
Carbinoxamine maleate 2.5 mg
Caffeine anhydride 25 mg
Thiamine nitrate (Vitamin B1 nitrate) 8 mg
Vitamin B2 4 mg
Indications For the relief of cold symptoms (Sore throat, cough, fever, runny nose, stuffy nose, sneezing, postnasal drip, headache, chills, joint pain)
Dosage For persons 15 years of age and over, three doses of three tablets each per day
Date of release February 1, 2002 (30-tablet size)
March 4, 2002 (45-tablet size)
Expected sales 3.0 billion yen in the first year (shipment basis, total for both package sizes)